HB869

Provides relative to expand glucose-improving medications coverage to individuals based on body mass index (OR INCREASE EX See Note)

Introduced·2/27/26
Ment Text

Louisiana HB869 expands health insurance coverage to include injectable drugs for glucose level improvement or weight loss.

Louisiana HB869 mandates that health coverage plans in the state provide coverage for injectable drugs approved by the FDA for lowering glucose levels or for weight loss. This applies if the drug is prescribed for prediabetes, gestational diabetes, or obesity, and the individual is diagnosed with one of these conditions. The coverage may include annual deductibles, coinsurance, and copayments, and may require prior authorization. The law also allows plans to mandate participation in a lifestyle management plan, if available.

Included in complete analysis

  • Overview
  • Core Provisions
  • Implementation
  • Impact
  • Legal Framework
  • Critical Issues

See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.

Where it stands

Current
Insurance Committee
Next
Committee decision

Sponsors

D
1
0
Democratic CaucusRepublican Caucus

History

Mar 9

House

Read by title, under the rules, referred to the Committee on Insurance.

Feb 27

House

Prefiled.

Feb 27

House

Under the rules, provisionally referred to the Committee on Insurance.